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Contact patternBackground: Respiratory syncytial virus (RSV) is the major viral cause of infant and childhood lower res-
piratory tract disease worldwide. Defining the optimal target product profile (TPP) is complicated due to
a wide range of possible vaccine properties, modalities and an incomplete understanding of the mecha-
nism of natural immunity. We report consensus population level impact projections based on two math-
ematical models applied to a low income setting.
Method: Two structurally distinct age-specific deterministic compartmental models reflecting uncer-
tainty associated with the natural history of infection and the mechanism by which immunity is acquired
and lost were constructed. A wide range of vaccine TPPs were explored including dosing regime and
uptake, and effects in the vaccinated individual on infectiousness, susceptibility, duration of protection,
disease severity and interaction with maternal antibodies and natural induced immunity. These were
combined with a range of vaccine implementation strategies, targeting the highest priority age group
and calibrated using hospitalization data from Kilifi County Hospital, Kenya.
Findings: Both models were able to reproduce the data. The impact predicted by the two models was
qualitatively similar across the range of TPPs, although one model consistently predicted higher impact
than the other. For a proposed realistic range of scenarios of TPP combinations, the models predicted up
to 70% reduction in hospitalizations in children under five years old. Vaccine designs which reduced the
duration and infectiousness of infection were predicted to have higher impacts. The models were sensi-
tive to the coverage and rate of loss of vaccine protection but not to the interaction between vaccine and
maternal/naturally acquired immunity.
Conclusion: The results suggest that vaccine properties leading to reduced virus circulation by lessening
the duration and infectiousness of infection upon challenge are of major importance in population RSV
disease control. These features should be a focus for vaccine development.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Background
A major burden of respiratory syncytial virus (RSV) arises from
infection in the first year of life, particularly the first 3–6 months of
life where resultant disease is most severe, most hospitalizations
occur and mortality is highest [1]. There are an estimated 3 million
cases of severe lower respiratory tract infection and up to 200,000
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RSV [1]. While RSV disease is globally important, the greatest share
of the childhood burden is found in the developing world [1].
Hence, while vaccines are needed for both developing and devel-
oped countries, we focus in this paper on the low resource setting.
The RSV vaccine pipeline is healthy, with over 60 vaccines under
development, and whilst most are at pre-clinical or early clinical
stages, two are in phase 2 trials and one in phase 3 [2].
In this context, we undertook to model the potential impact of
vaccination against RSV infection and disease with respect to the
possible vaccine target product profiles (TPPs) and delivery
options, and specifically in relation to reduction in early childhood
hospitalization. This gives rise to some challenges including the
unpredictable response of vaccine due to immature immunity of
infants and interaction with maternally derived specific antibodies.
Further challenges arise from uncertainties in the mechanisms of
acquisition and waning of immunity and the natural history of
RSV. Specifically, there is poor understanding of the relationship
between susceptibility to RSV infection and repeated exposure. If,
for instance, vaccination leads to a reduction in the rate of infection
with RSV, how would that impact on the immunity or susceptibil-
ity population profile? Different scenarios of waning immunity
lead to different modelling structures [3,4]. Whereas models fre-
quently address uncertainty in the form of sensitivity analyses, in
few instances is structural uncertainty investigated [5–7]. As a con-
sequence, in this study, two structurally distinct mathematical
models of RSV were constructed independently, from which to
identify consensus predictions: although the consensus modelling
approach has been explored for RSV previously [8,9], it is the first
time to include full age-structure and to be used in the context of
RSV vaccination. The findings should inform the potential individ-
ual and population-level benefits of defined vaccine properties, to
anticipate possible limitations in vaccine designs, and galvanize
discussion among various vaccine stakeholders early in a vaccine’s
development.2. Materials and methods
2.1. Data
Data sets from coastal Kenya were used in the modelling exer-
cise representative of the epidemiology of RSV in the low income
setting. These data define population demographic structure, age-
specific contact rates and age- and time-related RSV diagnosed
hospitalization data.2.2. Kenya demographic data
The age-specific fertility and mortality rates used in the model
were obtained from the registers of the Kilifi Health and Demo-
graphic Surveillance System (KHDSS) for the mid-year estimates
for 2007. For more information on the KHDSS, please refer to Scott
et al. [10] (see the Supplementary file 3E).2.3. Kenya age-specific contact rates
Diary contact data from a study conducted in the Kilifi KHDSS
[11] were used to construct a matrix of age-specific daily rates of
contacts with different individuals from which to estimate a
‘Who Acquires Infection FromWhom’ (WAIFW) matrix that is cen-
tral to the age-related transmission compartmental models [12].
The method has been described elsewhere [4] (see the Supplemen-
tary file 3E).2.4. Kenya disease surveillance dataset used to optimise the model pre-
vaccination
We used numbers of laboratory diagnosed RSV paediatric sev-
ere or very severe pneumonia hospital admissions stratified by
age and time from paediatric admissions surveillance to Kilifi
County (formally District) Hospital coastal Kenya from Oct 2004
to Dec 2010 [13]. Monthly case reports stratified by the monthly
age classes for the first two years of life and then yearly from age
24 to 59 months. Each model was fitted to (i) monthly admissions
pooled across all age classes and (ii) average numbers of admis-
sions over the time period by age class.
2.5. Ethics statement
Approval for using the secondary data from Kenya was obtained
from the KEMRI-Wellcome Trust Research Programme’s Data
Governance Committee.
2.6. Models
Two age-stratified deterministic compartmental mathematical
models for simulating the transmission dynamics of RSV were
developed. Each had similar layers of structure, namely, demo-
graphic, epidemiological, seasonality, disease related and vaccine
design and administration. The two models differed, however, in
epidemiological structure reflecting uncertainty associated with
the natural history of infection and particularly with the mecha-
nism by which immunity was acquired and lost. The key difference
between the twomodels was that one models sequential infections
leading to acquisition of a partially immune state that was lifelong
(SAI model) [4], whereas the other model assumed that a partially
immune state was maintained only by repeated or boosting infec-
tions and wanes in the absence of challenge (BWI model) [3]. In
other ways the models were harmonised with respect to the model
parameterisation and calibration to allow reasonable comparison
of output. Full details of each of the two models and the standard
technique for model fitting are to be found in the Supplementary
materials.
2.7. Vaccination framework
A vaccination framework was developed to interact with the
epidemiological sub-model and facilitate the evaluation of vacci-
nes TPPs and delivery strategies. A projection of the population-
level impact of vaccination has to account for the uncertainties
about the effectiveness of the future vaccines, in particular the
types of effects of the vaccine such as: (i) reduction in risk of infec-
tion, (ii) reduction in the duration or (iii) the magnitude of viral
shedding, (iv) reduction in the risk of upper respiratory tract infec-
tion (URTI), (v) reduction in the risk of lower respiratory tract
infection (LRTI) or (vi) severe lower respiratory tract infection
(SLRTI). There are also uncertainties about the duration of vaccine
protection, the natural history of RSV to be accounted for, in partic-
ular how the natural immunity builds up after the first and subse-
quent RSV infections and the interactions of these vaccines with
natural immunities i.e. maternal and from prior natural exposures.
We explored a wide range of TPPs which are detailed in the follow-
ing section. Fig. 1 shows vaccine implementation in the SAI and
BWI models up to two doses for simplicity.
2.8. Vaccine target product profiles (TPPs)
We divide the vaccine TPP into the seven components described
as follows. In all instances below we show the baseline choices in
bold type.
Fig. 1. Schema for vaccination implementation in (A) SAI model and (B) BWI model. Arrows show the direction of individuals on receipt of vaccine (moving right) or on loss of
vaccine effects due to waning immunity (moving left).
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The vaccine candidates can potentially have any combination of
the following effects on vaccinated individuals in relation to risk of
infection and outcomes following infection while the baseline is
the combination of all baseline choices in all effects (see Table 1).
2.8.2. Dosing regimen
Infant vaccination was assumed to be either through two or
three doses and at various ages of delivery as follow:
(i) 2 doses at 0 and 2 months of age
(ii) 2 doses at 2 and 4 months of age (baseline choice)
(iii) 3 doses at 0, 1 and 2 months of age
(iv) 3 doses at 2, 4 and 6 months of age
For the SAImodel routine (universal) vaccination is implemented
as individuals pass through an age–gateway, e.g. for vaccination at
age 2 months, a proportion of individuals are vaccinated as theytransition out of age 1 month based on the demographic schedule.
For theBWImodel a vaccination rate is applied to individuals as they
pass the age-gateway such that a proportion equal to the required
final coverage is attained within a short time period (3 days after
the vaccination age). Numerically, this represents aminor difference
between the two models (see the Supplementary file 3C).
2.8.3. Waning vaccine effect
Two options for average duration of vaccine effect are 1 year
(baseline choice) and 2 years. For the SAI model the rate of flow
from Dose n to Dose (n  1) is t i.e. 1/t is the average duration
of effect of each dose, and for the BWI the rate of flow from Dose
n to Dose 0 is t i.e. 1/t is the average duration of vaccine effect irre-
spective of number of doses.
2.8.4. Coverage and compliance combinations
We assumed a per dose compliance of either 90% or 100%
(baseline choice). Poor compliance was applied only when the
Table 1
Vaccine effects – low, medium and high. The bold figures represent the baseline values used when comparing different TPPs.
Effecta Low Medium High Note and references
(i) Risk of primary
infection reduction
0% 25% 50% Respiratory vaccines tend not to generate sterilizing immunity in humans. Some pre-clinical data obtained with
mucosally-administered viral-vectored RSV vaccine candidates suggest that the sterilizing immunity (no
evidence of infection) of 50% can be achieved [14]
(ii) Duration of infectivity
reduction
0% 50% 75% Evidence from the RSV vaccines in pre-clinical models [14,15] and from several influenza vaccines in animal
models and human [16–18]. Antiviral candidates targeting RSV F protein mediated-fusion [19], a mechanism
also targeted by RSV protein F-based vaccines, have been shown to reduce the level and duration of shedding in
human challenge studies [20]
(iii) Infectiousness
reduction
0% 50% 75%
(iv) Risk of URTI reduction 0% 50% 75% Influenza vaccines offer relatively modest efficacy against milder (URTI) disease but greater protection against
more severe disease forms [21]. For RSV, preclinical model suggested that ten-fold higher neutralizing antibody
levels are required to offer protection against upper, compared to lower, respiratory tract infection [22]. A 70% or
higher efficacy against severe RSV disease seems a reachable goal considering the 78% efficacy observed with the
monoclonal preparation Palivizumab in premature infants without bronchopulmonary dysplasia [23]
(v) Risk of LRTI reduction 50% 70% 90%
(vi) Risk of severe LRTI
(SLRTI) reduction
50% 70% 90%
a Relative to the infected state in unvaccinated individuals.
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erage of 90% would not allow compliance at 90% for more than one
dose because two doses at 90% compliance would imply that the
first dose coverage must exceed 100%. The designated final cover-
age levels were 50%, 70% and 90% (baseline choice).
2.8.5. Interaction with maternal antibodies
A range of scenarios are plausible for the potential interaction of
an infant vaccine in the presence of a maternal antibody presence
that is waning. Wemainly focused on three options which were: (i)
‘‘No interaction” (baseline choice), (ii) ‘‘Bounce up” and (iii)
‘‘Drop back” (see the Supplementary file 3A).
2.8.6. Interaction with natural immunity
Three options of effects of vaccination of individuals with natu-
ral immunity were explored: (i) ‘‘No effect” (baseline choice), (ii)
‘‘Multiplicative” and (iii) ‘‘Top-up” (see the Supplementary file 3B).
2.8.7. Maternal vaccination
We assume that if children are born to mothers who received
maternal vaccination they would be similarly affected as if vacci-
nated as infants but with the protection commencing from birth
and lasting for either 3 months (baseline choice) or 6 months.
The final vaccine coverage considered here are 25%, 50% (baseline
choice) and 75%. Implementation is identical to the process of
infant vaccination for each model with a per dose compliance of
either 90% or 100% (baseline choice) (see the Supplementary file
3D).
2.9. Sensitivity analysis
We approach the sensitivity analysis in two stages, one-way
and multi-way analyses (see the Supplementary file 1).
3. Results
Both models could demonstrate reasonable fitting to the Kenya
hospitalization data by time and age classes (see Fig. 2).
The main outcome impact prediction of the models is the per-
centage reduction in the number of under 1 and 5 year old hospital
admissions after first 10 years of the vaccination programme when
compared to the pre-vaccination average. The highlights of the
projections of the impact of vaccine TPPs using the two model
structures (SAI and BWI) are described in Figs. 3 and 4.
SAI model (left column) and BWI model (right column) predic-
tions of impact of vaccine TPPs on annual hospitalizations of (a)
infants under 1 year old over time since vaccination begins (top
row); (b) children under 5 years old over time since vaccination
begins (middle row); (c) age profiles 10 years after the vaccinationprogramme begins (bottom row). Each graph plots the no-vaccine
model fit (bold solid red line), the median prediction from all TPPs
(solid green line), the 95% prediction limits from all TPPs (dashed
green line) and the baseline TPP prediction (solid grey line).
From Fig. 3, it can be seen that the median impact (solid green
lines), which is very similar to that for the baseline parameter set
(solid grey lines), is a 50% reduction or more within a year of two
of vaccine introduction. The impact tends to be highest early into
the vaccine era, with a degree of rebound 5–6 years following vac-
cine introduction. The projected impact is greater for the BWI
model than for the SAI, although the latter is more stable over time.
The projected impact by age is in proportion to the pre-vaccine
age-related admission proportion.
The key difference between the models is the magnitude of the
projected impact. This is a result of the force of infection required
to fit the SAI model being higher than that for the BWI model (see
the Supplementary file 2 for the model parameter estimates). A
preliminary exploration of both models indicated that increasing
the force of infection in the BWI model will reduce the predicted
impact and that reducing the force of infection in the SAI model
will increase the predicted impact (results not shown).
Analyses of the degree of influence of specific TPP component
characteristics on the impact of vaccination are summarised in
Fig. 4. Specifically, this explores the relative benefits of the differ-
ent possible vaccine ‘effects’ (see Section 2.8.1.). These results
record the univariate linear regression coefficients of change in
impact, defined as percentage reduction in under 5 year olds hos-
pitalized, as the level of effect changes (e.g. percent reduction in
risk of infection afforded by the vaccine). The outcome measure
is thus the degree of influence of a change of effect (of a particular
type) on the reduction in the under 5 year old hospitalization. For
example, keeping other factors constant, for each 1 unit (i.e. 1%)
increase in vaccine effect on risk of infection, we expect a 0.062%
and 0.134% reduction in the under 5 year old hospitalization for
SAI and BWI model, respectively.
Fig. 4 clearly indicates the relatively important additional ben-
efits of a vaccine that would be able to reduce infectiousness and/
or the duration of infection upon RSV-related hospitalization in
<5 year old. Other vaccine effects are less influential, i.e. changes
in per person risk of infection or of disease arising following infec-
tion (whether URTI, LTRI or severe LRTI). There is broad agreement
between the two models, but the SAI projects markedly greater
impact for the effect of reducing SLRTI risk, while the BWI pro-
jected markedly greater impact for risk of infection and risk of
URTI. Both models projected less impact of maternal vaccination
when compared with infant vaccination. Reduction in hospitaliza-
tions for the majority of the TPPs for maternal vaccination evalu-
ated were in the region of 7% (SAI model) and 15% (BWI model)
(see the Supplementary file 3D).
Fig. 2. Calibrated fits of the two RSV models for the Kenya setting (black line, SAI; grey line, BWI). (A) Models calibrated using Kilifi, Kenya RSV hospital surveillance monthly
time series 2004–2011 (blue markers, upper panel) and (B) the average profile (blue markers and error bars for 95% CI) for annual hospitalized cases stratified by monthly age
classes.
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the one-way sensitivity analysis, agreeing with the prediction that
the most significant impact on hospitalization of children under
5 years of age would be achieved using a vaccine design with
reduced duration of infection and infectiousness. The multi-way
analysis also agreed on the significance of duration of immunity,
compliance and coverage on the predicted impacts. Finally, the
multi-way analysis affirmed that therewas no significant difference
in the impact of the vaccine given different assumptions about the
vaccine interactions with the maternal and naturally acquired
immunity (see the Supplementary file 3A and 3B), or assumptions
on the dose and various vaccination schedules (see the Supplemen-
tary file 3C). Overall the predictions for infant vaccination are
strengthened by the fact that similar results arise from two models
with different epidemiological structure. Investigations so far sug-
gest uncertainty of the impact of a maternal vaccine, where both
models showed relatively different impact of this type of vaccina-
tion when compared with the infant vaccinations.4. Discussion
We report on an investigation of the potential population level
impact of a range of vaccination strategy options, using an array of
vaccine properties and vaccination schedules called TPPs, on dis-
ease arising from RSV using two transmission dynamic models.In agreement, both models showed the maximum reduction of
RSV hospitalization obtained from the vaccine effects on shorten-
ing duration and lowering infectiousness of RSV infection. This
‘‘herd protection effect” could most likely be explained by a signif-
icant fall in transmission in the risk group in which there was the
strongly age-specific risk of severe disease coupled with age-
homophilic (assortative) mixing patterns. The importance of indi-
rect protection in the control of RSV is in accord with earlier pub-
lished findings [4]. This could be related to the age specific contact
pattern and that may be setting/country specific, thus it would be
worthwhile to repeat the analysis in different settings.
The study provides a degree of robustness not frequently used
in modelling evaluations of the potential impact of vaccination
by undertaking a consensus analysis involving two models [6].
The findings from the two models are qualitatively similar and in
some areas in quantitative agreement. Furthermore, what is unu-
sual in this study is the emphasis placed on evaluating the proper-
ties associated with the vaccine in order to provide information
that is of use in the process of vaccine development. For example,
we show by sensitivity analysis that two key areas to focus on in
vaccine design is the influence of the vaccine on reducing the dura-
tion and infectiousness of challenge infection subsequent to vacci-
nation. These are in part altruistic properties of the vaccine insofar
as they work by increasing the indirect benefits of vaccination to
the unvaccinated.
Fig. 3. Comparison of predicted impact of routine infant RSV vaccination using two models, SAI model (left column) and BWI model (right column) i.e. predictions of impact
of vaccine TPPs on hospitalizations of: infants under 1 year old over time since vaccination begins (a and b); children under 5 years old over time since vaccination begins (c
and d); age profiles 10 years after vaccination begins (e and f). Each graph plots the non-vaccine model fit (bold solid red line), the median prediction from all TPPs (solid
green line), the 95% prediction limits from all TPPs (dashed green line) and the baseline TPP prediction (bold solid grey line).
Fig. 4. Comparison of change in impact arising from changes in any one of the six ‘effect’ properties of a RSV vaccine (green for SAI; blue for BWI). Univariate regression of
impact (percentage reduction in under 5 hospitalization) against the slope of the regression lines which measured the rate of change of impact for each of six ‘effect’
characteristics.
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vaccine strategy are (i) as expected, longer duration of protection
and higher coverage, but also (ii) reductions in the duration of
infection and degree of infectiousness are strongly influential.
The lower incremental benefit from a vaccine reducing the risk of
primary infection appears at first paradoxical. However, the sce-
narios chosen were of relatively low effect (up to 50%). The vaccine
impact appears also insensitive to the possible interactionsbetween the vaccine and existing immunity, for both acquired
and passive antibodies.5. Summary of the key findings
(1) The impact projected by the two models is qualitatively sim-
ilar across the range of TPPs.
W. Pan-Ngum et al. / Vaccine 35 (2017) 403–409 409(2) The TPP options with highest predicted impacts offer signif-
icant reduction in hospitalizations of children under 5 years
of age (around 70%).
(3) Vaccine characteristics that reduce the duration and infec-
tiousness of infections in vaccinees are projected to have
the greatest impact on hospitalized RSV. This is a conse-
quence of a strong herd immunity effect of the vaccine
programme.
(4) The impact of vaccination targeted at pregnant women is
found to be model dependent, with minimal impact pre-
dicted for one model compared with the other. This is an
interesting area for further research.
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